A similar sensitivity was observed in this study, with methylation of BCAT1 and/or IKZF1 detected in plasma from 6/10 (60%) stage IV patients, demonstrating the successful use of the combination of CNA and EpiTect kits for detection of these biomarkers in blood from colorectal cancer patients. This evidence concerns the gene IKZF1 and colorectal cancer.